The anesthesia kits produced by Camelot Group account for one-third of the national market share, the analgesic pumps account for one-fifth of the national market share, the central venous catheter, tracheal intubation, respiratory circuits are all leading sales in the Chinese market, and the double-safety indwelling needles are the first in the world; the hospitals of Grade 2A and above in Beijing are covered by 100% of the total number of hospitals. Our products have been sold to Finland, Russia, Germany, India, Iran, Italy, South Korea and other European and African countries and regions under our own brand name. Camelot's English trademark has been registered in more than ten countries, such as UK, USA, South Korea, India and so on!
In January 2011, the University-Industry Research Project was recognized by the Ministry of Science and Technology, and the "Camelid Medical Device Science and Technology Innovation Award" became the first medical device innovation award ministry-level project founded by Chinese social forces. Until 2012, Camelid Group has successfully held four sessions of Industry-University-Research Summit Forum. 2012 April, Camelid Group undertook two national science and technology support program project topics - small diameter artificial blood vessels and new plasticizer biomedical materials approved by the Ministry of Science and Technology of the People's Republic of China, and allocated ten million yuan of the subject of the fund; September, Camelid Group and Beijing University of Aeronautics and Astronautics ********. and Beijing University of Aeronautics and Astronautics*** together to build the "camelid - Beihang biomedical materials and devices research center" was formally established, but also become a number of universities in Beijing, Shanghai, Henan and other internship training base.
In 2011, Camelot Group invested in the construction of the third factory - Camelot Health Science and Technology Industrial Park, which covers a total area of 500 acres with a total investment of 1.5 billion RMB. The industrial park will take polymer materials, electronics and metal technology as the core technology, hemodialysis, minimally invasive intervention, oral materials, medical consumables in the field of inspection and testing as the leading industry, and make every effort to build a world brand of medical devices!